During a recent press conference organized by the Awaken India Movement (AIM), doctors raised concerns regarding the safety of the Covishield vaccine, manufactured by the Serum Institute of India, in light of revelations made by AstraZeneca in a UK court about potential rare cases of blood clots associated with their COVID-19 vaccine. The doctors urged the government to conduct a thorough review of the scientific basis of all COVID-19 vaccines. They also called for audits of the commercialization process and the implementation of active surveillance and monitoring mechanisms to swiftly identify any adverse events related to vaccination. This collective effort aims to ensure the safety and efficacy of COVID-19 vaccines and bolster public trust in vaccination campaigns.
“The government has wholly ignored the rising number of cases of tragic deaths post-Covid vaccination all the while and continues to promote Covid vaccines as ‘safe and effective’, without scientific investigation and invoking epidemiology,” Dr Tarun Kothari, a radiologist and an activist, stated at the press conference.
During a recent discussion, Dr. Sujata Mittal, a gynecologist and oncologist, highlighted the emergence of a side effect associated with COVID-19 vaccines known as Thrombosis with Thrombocytopenia Syndrome (TTS). She expressed concern over the lack of awareness surrounding the administration of COVID-19 vaccines before the completion of phase-3 trials. Dr. Mittal emphasized that the vaccines were being rolled out without comprehensive data on potential short-term or long-term side effects, including fatalities. This underscores the importance of thorough research and evaluation to ensure the safety and efficacy of vaccination campaigns.
The concerning lack of awareness surrounding vaccine injuries, particularly in India. She pointed out that this low awareness extends to vaccine-related issues such as abnormalities in menstrual cycles. Dr. Mittal noted that thousands of women reported such abnormalities, which were later confirmed as a side effect of the vaccine in a study published in September 2022. This delay in recognition underscores the importance of vigilance and thorough investigation into potential side effects of vaccines to ensure the safety and well-being.
“The Awaken India Movement (AIM) has been collecting details of Covid Vaccine deaths covered by media/social media in India and sharing them with various high authorities of the country since 2021, when the vaccination began. The government has failed to respond to our repeated requests to investigate deaths and debilitation from adverse effects of vaccination,” Dr Kothari stated.
The Awaken India Movement (AIM) has called upon the Indian government to provide compensation to all individuals affected by COVID-19 vaccines, as well as their family members. They advocate for a compensation mechanism that involves not only the government but also the vaccine manufacturers.
“We also demand establishing fast track courts and vaccine courts to provide swift justice to the vaccine injured and their families,” Dr Mittal stated.
In addition to advocating for compensation for vaccine-related injuries, the Awaken India Movement (AIM) emphasizes the importance of implementing active surveillance and monitoring mechanisms. Dr. Sujata Mittal stressed the necessity of promptly identifying vaccine adverse events to enable early intervention and treatment. She called for the development and widespread dissemination of early treatment protocols to potentially save lives.
“Review science behind all Covid vaccines and audit their commercialisation,” Dr Kothari stated.
AstraZeneca, based in the United Kingdom, has announced the global withdrawal of its COVID-19 vaccine, which was distributed in India under the name ‘Covishield’ in collaboration with the Serum Institute of India. This decision comes in the wake of AstraZeneca’s recent acknowledgment of rare side effects associated with the vaccine, including blood clotting and decreased platelet counts.
The company cited a surplus of updated vaccines available since the onset of the pandemic as the reason behind the withdrawal. In India, AstraZeneca’s partner, the Serum Institute of India, confirmed that it ceased the production and distribution of additional doses of Covishield in December 2021. The Serum Institute reiterated that it had previously disclosed all rare to very rare side effects, including Thrombosis with Thrombocytopenia Syndrome (TTS), in the vaccine’s packaging insert in 2021.
AstraZeneca, in collaboration with Oxford University, developed the COVID-19 vaccine, which was marketed as Vaxzevria in Europe. The decision to withdraw the vaccine globally reflects the company’s response to the evolving landscape of COVID-19 vaccination efforts and ongoing considerations regarding vaccine safety and efficacy.
Disclaimer:
The information contained in this article is for educational and informational purposes only and is not intended as a health advice. We would ask you to consult a qualified professional or medical expert to gain additional knowledge before you choose to consume any product or perform any exercise.
